Apogee Therapeutics, Ownership

APGE Stock   39.89  0.95  2.33%   
The majority of Apogee Therapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Apogee Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Apogee Therapeutics,. Please pay attention to any change in the institutional holdings of Apogee Therapeutics, Common as this could imply that something significant has changed or is about to change at the company.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apogee Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Apogee Stock Ownership Analysis

About 89.0% of the company shares are held by institutions such as insurance companies. The book value of Apogee Therapeutics, was presently reported as 12.35. The company recorded a loss per share of 3.3. Apogee Therapeutics, had not issued any dividends in recent years. For more info on Apogee Therapeutics, Common please contact Michael MD at 650 394 5230 or go to https://www.apogeetherapeutics.com.
Besides selling stocks to institutional investors, Apogee Therapeutics, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Apogee Therapeutics,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Apogee Therapeutics,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Apogee Therapeutics, Quarterly Liabilities And Stockholders Equity

1.06 Billion

About 11.0% of Apogee Therapeutics, Common are currently held by insiders. Unlike Apogee Therapeutics,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Apogee Therapeutics,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Apogee Therapeutics,'s insider trades

Apogee Therapeutics, Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apogee Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apogee Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apogee Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Henderson Michael Thomas over two weeks ago
Disposition of 2674 shares by Henderson Michael Thomas of Apogee Therapeutics, at 30.62 subject to Rule 16b-3
 
Henderson Michael Thomas over a month ago
Disposition of 15000 shares by Henderson Michael Thomas of Apogee Therapeutics, at 40.58 subject to Rule 16b-3
 
Henderson Michael Thomas over a month ago
Disposition of 8500 shares by Henderson Michael Thomas of Apogee Therapeutics, at 22.86 subject to Rule 16b-3
 
Dambkowski Carl over two months ago
Disposition of 100 shares by Dambkowski Carl of Apogee Therapeutics, at 47.92 subject to Rule 16b-3
 
Henderson Michael Thomas over two months ago
Disposition of 2868 shares by Henderson Michael Thomas of Apogee Therapeutics, at 49.38 subject to Rule 16b-3
 
Dambkowski Carl over two months ago
Disposition of 1360 shares by Dambkowski Carl of Apogee Therapeutics, at 22.86 subject to Rule 16b-3
 
Dambkowski Carl over three months ago
Disposition of 1815 shares by Dambkowski Carl of Apogee Therapeutics, at 22.86 subject to Rule 16b-3
 
Mckenna Mark C. over three months ago
Acquisition by Mckenna Mark C. of 7500 shares of Apogee Therapeutics, at 49.02 subject to Rule 16b-3
 
Dambkowski Carl over three months ago
Disposition of 1815 shares by Dambkowski Carl of Apogee Therapeutics, at 22.86 subject to Rule 16b-3
 
Dambkowski Carl over three months ago
Acquisition by Dambkowski Carl of 124962 shares of Apogee Therapeutics, at 49.07 subject to Rule 16b-3
 
Henderson Michael Thomas over three months ago
Disposition of 1672 shares by Henderson Michael Thomas of Apogee Therapeutics, at 47.19 subject to Rule 16b-3
 
Henderson Michael Thomas over three months ago
Disposition of 1000 shares by Henderson Michael Thomas of Apogee Therapeutics, at 59.94 subject to Rule 16b-3

Apogee Therapeutics, Corporate Filings

8K
11th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
7th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
3rd of March 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
14th of February 2025
Other Reports
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Apogee Therapeutics, is a strong investment it is important to analyze Apogee Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apogee Therapeutics,'s future performance. For an informed investment choice regarding Apogee Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apogee Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apogee Therapeutics,. If investors know Apogee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apogee Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.30)
Return On Assets
(0.23)
Return On Equity
(0.33)
The market value of Apogee Therapeutics, is measured differently than its book value, which is the value of Apogee that is recorded on the company's balance sheet. Investors also form their own opinion of Apogee Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Apogee Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apogee Therapeutics,'s market value can be influenced by many factors that don't directly affect Apogee Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apogee Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Apogee Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apogee Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.